Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.6 CAD | +2.38% | +0.58% | -6.72% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Sales 2024 * | 35M 25.53M | Sales 2025 * | 38.7M 28.23M | Capitalization | 97.52M 71.13M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.52 x |
P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
15
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.46% |
Latest transcript on BioSyent Inc.
1 day | +2.38% | ||
1 week | +0.58% | ||
Current month | -1.15% | ||
1 month | -1.15% | ||
6 months | +9.28% | ||
Current year | -6.72% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 8.6 | +2.38% | 23 020 |
24-04-23 | 8.4 | 0.00% | 2,777 |
24-04-22 | 8.4 | -1.18% | 3,736 |
24-04-19 | 8.5 | +0.59% | 2,700 |
24-04-18 | 8.45 | -1.17% | 3,772 |
Delayed Quote Toronto S.E., April 24, 2024 at 12:23 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.72% | 71.33M | |
+25.96% | 672B | |
+25.87% | 570B | |
-5.56% | 360B | |
+16.06% | 321B | |
+8.65% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.96% | 149B |
- Stock Market
- Equities
- RX Stock